Checking the 'male': FDA testosterone scrutiny puts squeeze on Testim
By Randy Osborne
Thursday, May 8, 2014
Wider meaning of the 76 percent drop in first-quarter Testim sales related to the prospects for Testopel may not be simple, but Auxilium Pharmaceuticals Inc.'s former (a gel) is apparently on the skids and the latter (a long-acting implantable therapy) falls as well into a suddenly risky field: testosterone replacement therapy (TRT).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.